Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the
blood-brain barrier during a study of patients with presumptive West Nile virus disease.
AVI-4065, which was designed to target HCV, is also a PMO; its ability to cross the
blood-brain barrier is unknown. In this study, a single dose of AVI-4065 will be
subcutaneously injected, and samples collected to determine if this drug crosses the
blood-brain barrier. If it does, then additional investigations could be performed in people
with severe forms of HCV disease in which the brain is affected.